[Individual glycoside therapy using serum concentration determination in heart insufficiency of horses].

The research explores the use of methyldigoxin, a form of cardiac glycoside, to treat heart failure in horses and a donkey, with dosage adjusted by monitoring serum concentration levels. It also evaluates the impact of other diseases and medicines on this approach.

Method and Participants

• The study involved a total of 24 participants, comprised of 23 horses and one donkey, all of which were suffering from congestive heart failure.
• Each animal was treated with a standardized dose of methyldigoxin (0.0032 mg/kg of body weight), a type of cardiac glycoside – a class of organic compounds that affect the heart muscle and are useful in the treatment of heart failure and arrhythmia.

Monitored Therapy

• To control the therapy, the researchers monitored the serum concentration of the cardiac glycoside in each animal’s blood.
• They noted that four of the horses had a higher than necessary serum concentration for therapeutic approach, while 13 horses had a lower level.

Influence of Additional Diseases and Medications

• The research also examined the effect of other diseases and medications on the methyldigoxin therapy.
• It suggests that these factors can potentially impact the serum concentration of cardiac glycoside, hence impacting the efficacy of the treatment.

Establishing Therapeutic Guidelines

• As a conclusion, the study offers a guideline for determining the individual therapeutic dose of glycoside, specifically methyldigoxin, based on the monitored serum concentration.
• While it doesn’t provide detailed specifics, the research indicates the importance of individualized dosage in glycoside therapy to ensure its efficacy and safety, taking into account not only the animal’s weight but also additional diseases and medications they may be dealing with.